Back to Report Store Home

Global Cardiovascular Disease Market to 2022 – Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • Published: Oct-2016
  • Report Code: GBIHC422MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Cardiovascular Disease Therapeutics Market, Global, Epidemiology Patterns for Hypertension, 2015–2022 20

Figure 2: Cardiovascular Disease Therapeutics Market, Global, Epidemiology Patterns for Dyslipidemia, 2015–2022 21

Figure 3: Cardiovascular Disease Therapeutics Market, Global, Epidemiology Patterns for Acute Coronary Syndrome, Ischemic Stroke and Venous Thromboembolism, 2015–2022 22

Figure 4: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Crestor ($bn), 2006–2022 30

Figure 5: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Zetia ($bn), 2006–2022 32

Figure 6: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Lipitor ($bn), 2006–2022 34

Figure 7: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Praluent ($bn), 2006–2022 35

Figure 8: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Xarelto ($bn), 2006–2022 37

Figure 9: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Eliquis ($bn), 2006–2022 38

Figure 10: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Plavix ($bn), 2006–2022 39

Figure 11: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Brilinta ($bn), 2006–2022 41

Figure 12: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Entresto ($bn), 2006–2022 42

Figure 13: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Benicar ($bn), 2006–2022 43

Figure 14: Cardiovascular Disease Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 45

Figure 15: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Cardiovascular Diseases by Stage of Development, Molecule Type and Program Type, 2016 46

Figure 16: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Key Cardiovascular Disease Indications by Stage of Development, 2016 47

Figure 17: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecule Type, 2016 48

Figure 18: Cardiovascular Disease Therapeutics Market, Global, Pipeline by Molecular Target, 2016 50

Figure 19: Cardiovascular Disease Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016 51

Figure 20: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecular Target, 2016 52

Figure 21: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2016 53

Figure 22: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2016 54

Figure 23: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2016 55

Figure 24: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2016 56

Figure 25: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2016 56

Figure 26: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2016 57

Figure 27: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2016 58

Figure 28: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2016 59

Figure 29: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2016 59

Figure 30: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2016 60

Figure 31: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2016 61

Figure 32: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2016 62

Figure 33: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2016 63

Figure 34: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2016 63

Figure 35: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2016 64

Figure 36: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2016 65

Figure 37: Cardiovascular Disease Therapeutics Market, Global, Market Size ($bn), 2015–2022 66

Figure 38: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015–2022 68

Figure 39: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Drugs Targeting Elements of the Coagulation Cascade ($bn), 2015–2022 70

Figure 40: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for P2Y12 Inhibitors ($bn), 2015–2022 71

Figure 41: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Beta Blockers ($bn), 2015–2022 72

Figure 42: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for PCSK9 Inhibitors ($m), 2015–2022 73

Figure 43: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for HMG-CoA Inhibitors ($bn), 2015–2022 73

Figure 44: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on RAS ($bn), 2015–2022 74

Figure 45: Cardiovascular Disease Therapeutics Market, Global, Forecast Market Share by Company (%), 2015–2022 77

Figure 46: Cardiovascular Disease Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2015–2022 78

Figure 47: Cardiovascular Disease Therapeutics Market, Global, Revenues by Product Type, 2015–2022 79

Figure 48: Cardiovascular Disease Therapeutics Market, Global, Sanofi Annual Revenue Forecast ($bn), 2015–2022 80

Figure 49: Cardiovascular Disease Therapeutics Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2015–2022 81

Figure 50: Cardiovascular Disease Therapeutics Market, Global, Novartis Annual Revenue Forecast ($bn), 2015–2022 82

Figure 51: Cardiovascular Disease Therapeutics Market, Global, Bayer Annual Revenue Forecast ($bn), 2015–2022 83

Figure 52: Cardiovascular Disease Therapeutics Market, Global, Pfizer Annual Revenue Forecast ($bn), 2015–2022 84

Figure 53: Cardiovascular Disease Therapeutics Market, Global, Merck Annual Revenue Forecast ($bn), 2015–2022 85

Figure 54: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Bococizumab ($m), 2018–2022 86

Figure 55: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Betrixaban ($m), 2017–2022 87

Figure 56: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Anacetrapib ($m), 2018–2022 88

Figure 57: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Volanesorsen ($m), 2017–2022 89

Figure 58: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Vericiguat ($m), 2018–2022 90

Figure 59: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for ETC-1002 ($m), 2018–2022 91

Figure 60: Cardiovascular Disease Therapeutics Market, Global, Cluster by Growth and Market Share, 2015–2022 92

Figure 61: Cardiovascular Disease Therapeutics Market, Global, Companies by Type, 2016 94

Figure 62: Cardiovascular Disease Therapeutics Market, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Cardiovascular Specialization, 2016 95

Figure 63: Cardiovascular Disease Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Cardiovascular Disease, 2015–2022 96

Figure 64: Cardiovascular Disease Therapeutics Market, Global, Top Six Companies, Proportion of Total Company Revenue Attributed to Cardiovascular Disease ($bn), 2015–2022 97

Figure 65: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals, 2006–2016 99

Figure 66: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals by Indication, 2006–2016 100

Figure 67: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals by Stage of Development and Value, 2006–2016 101

Figure 68: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2016 102

Figure 69: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals, 2006–2016 105

Figure 70: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals by Indication, 2006–2016 106

Figure 71: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006–2016 107

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards